Oxford BioMedica PLC (OXBDF)

[marcusl2]

Highlights from
the studies include: the ability of 5T4 CAR-T cells to kill
a wide range of 5T4-expressing tumour cell lines in vitro;
the ability of T cells taken from patients with ovarian
cancer to be re-programmed with the 5T4 CAR construct
and respond functionally to their own tumour cells
in vitro through the secretion of cytokines; and the ability
of 5T4 CAR-T cells to control tumour cell growth in
in vivo models. Further data will be presented in due
course either at a conference or in a publication.